UC San Diego

UC San Diego Previously Published Works

Title

Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency.

Permalink

<https://escholarship.org/uc/item/56j98290>

Authors

White, Cory H
Johnston, Harvey E
Moesker, Bastiaan
et al.

Publication Date

2015-11-01

DOI

10.1016/j.antiviral.2015.09.002

Peer reviewed

Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency

Cory H. White^{a,b}, Harvey E. Johnston^{c,d}, Bastiaan Moesker^e, Antigoni Manousopoulou^{d,e}, David M. Margolis^f, Douglas D. Richman^{b,g,h}, Celsa A. Spina^{b,g}, Spiros D. Garbis^{c,d,e,*}, Christopher H. Woelk^{e,*,1}, Nadejda Beliakova-Bethell^{h,*,1}

^a Graduate Program in Bioinformatics and Systems Biology, University of California San Diego, La Jolla, CA 92093, USA

^b San Diego VA Medical Center and Veterans Medical Research Foundation, San Diego, CA 92161, USA

^c Cancer Sciences Faculty of Medicine, University of Southampton, Southampton, Hants SO16 6YD, UK

^d Centre for Proteomic Research, Institute for Life Sciences, University of Southampton, Highfield Campus, Southampton, UK

^e Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, Hants SO16 6YD, UK

^f Departments of Medicine, Microbiology and Immunology, Epidemiology, University of North Carolina, Chapel Hill, NC, USA

^g Department of Pathology, University of California San Diego, La Jolla, CA 92093, USA

^h Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA

ARTICLE INFO

Article history:

Received 16 May 2015

Revised 22 August 2015

Accepted 3 September 2015

Available online 4 September 2015

Keywords:

HIV latency

Suberoylanilide hydroxamic acid

iTRAQ mass spectrometry

HMGA1

Autophagy

Protein folding

ABSTRACT

Suberoylanilide hydroxamic acid (SAHA) has been assessed in clinical trials as part of a “shock and kill” strategy to cure HIV-infected patients. While it was effective at inducing expression of HIV RNA (“shock”), treatment with SAHA did not result in a reduction of reservoir size (“kill”). We therefore utilized a combined analysis of effects of SAHA on the host transcriptome and proteome to dissect its mechanisms of action that may explain its limited success in “shock and kill” strategies. CD4⁺ T cells from HIV seronegative donors were treated with 1 μM SAHA or its solvent dimethyl sulfoxide (DMSO) for 24 h. Protein expression and post-translational modifications were measured with iTRAQ proteomics using ultra high-precision two-dimensional liquid chromatography–tandem mass spectrometry. Gene expression was assessed by Illumina microarrays. Using *limma* package in the R computing environment, we identified 185 proteins, 18 phosphorylated forms, 4 acetylated forms and 2982 genes, whose expression was modulated by SAHA. A protein interaction network integrating these 4 data types identified the HIV transcriptional repressor *HMGA1* to be upregulated by SAHA at the transcript, protein and acetylated protein levels. Further functional category assessment of proteins and genes modulated by SAHA identified gene ontology terms related to NFκB signaling, protein folding and autophagy, which are all relevant to HIV reactivation. In summary, SAHA modulated numerous host cell transcripts, proteins and post-translational modifications of proteins, which would be expected to have very mixed effects on the induction of HIV-specific transcription and protein function. Proteome profiling highlighted a number of potential counter-regulatory effects of SAHA with respect to viral induction, which transcriptome profiling alone would not have identified. These observations could lead to a more informed selection and design of other HDACi with a more refined targeting profile, and prioritization of latency reversing agents of other classes to be used in combination with SAHA to achieve more potent induction of HIV expression.

© 2015 Elsevier B.V. All rights reserved.

Abbreviations: SAHA, suberoylanilide hydroxamic acid; DEPs, differentially expressed proteins; DAPs, differentially expressed acetylated forms of proteins; DPPs, differentially expressed phosphorylated forms of proteins; DEGs, differentially expressed genes; UCSD, University of California San Diego.

* Corresponding authors at: Faculty of Medicine, Cancer Sciences and CES Units, Institute for Life Sciences, University of Southampton, 3001, Life Sciences Building 85, Highfield Campus, Southampton SO17 1BJ, UK (S. Garbis). Faculty of Medicine, University of Southampton, Southampton General Hospital, South Academic Block, Room Number: SGH/LE74/MP811, Mail point 811, Tremona Road, Southampton SO16 6YD, UK (C. Woelk). University of California San Diego, Department of Medicine, Stein Clinical Research Building, Rm. 303, 9500 Gilman Drive, #0679, La Jolla, CA 92093-0679, USA (N. Beliakova-Bethell).

E-mail addresses: s.d.garbis@soton.ac.uk (S.D. Garbis), c.h.woelk@soton.ac.uk (C.H. Woelk), nbeliako@ucsd.edu (N. Beliakova-Bethell).

¹ These senior authors contributed equally to this manuscript.

1. Introduction

The persistent cellular reservoir of HIV provirus is a major obstacle to a cure (Richman et al., 2009). The “shock and kill” treatment strategy has been envisioned as a controlled induction of virus reactivation in the presence of combination antiretroviral therapy (cART) to reveal latently infected cells for immune system recognition and destruction (Ylisastigui et al., 2004). Histone deacetylase (HDAC) inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA), an FDA-approved compound for treatment of cutaneous T cell lymphoma (Mann et al., 2007), has been used in clinical trials to reactivate HIV to reduce the size of the latent reservoir (Archin et al., 2014; Archin et al., 2012; Elliott et al., 2014). Exposure to HDACis is tightly associated with histone hyperacetylation and chromatin decondensation, which provides a transcriptionally favorable environment for HIV reactivation (Matalon et al., 2011). SAHA was effective at inducing HIV RNA expression in most patients on cART with suppressed viremia (Archin et al., 2012; Elliott et al., 2014); however, treatment with SAHA did not result in a reduction of reservoir size (Archin et al., 2014; Elliott et al., 2014). SAHA is also used as a synergistic agent to screen *in vitro* for other latency reversing agents (LRAs); therefore, limitations of its activity require further elucidation. Understanding potential counter-regulatory effects of SAHA on HIV reactivation will guide the selection of modifications of this compound and prioritization of LRAs in combination therapies.

SAHA was well tolerated in HIV-infected patients (Archin et al., 2014, 2012; Elliott et al., 2014), and an *in vitro* treatment of primary CD4⁺ T cells with a physiological concentration of SAHA elicited only modest effects on gene expression (Beliakova-Bethell et al., 2013). However, genes induced by SAHA may specifically regulate the state of HIV latency (Shirakawa et al., 2013), so that the net effect of SAHA on these genes results in insufficient viral induction to kill a cell. The function of non-histone targets of HDACs (e.g., chaperone protein HSP90) may also be modulated by SAHA (Choudhary et al., 2009). SAHA binds not only HDACs, but other proteins as well (Bantscheff et al., 2011), opening the possibility for direct regulation of additional targets. A non-histone effect of SAHA relevant to HIV reactivation was previously demonstrated by the Peterlin group (Contreras et al., 2009). In this case, SAHA promoted HIV reactivation by causing the release of positive transcription elongation factor (p-TEFb) from its inactive complex, which is required for Tat-mediated transcriptional elongation. Ultimately, multiple steps in the HIV replication cycle have to be successfully completed to reveal the infected cell to the immune system. These include cell signaling leading to proper assembly of transcription factors on the long terminal repeat (LTR), transcription, RNA splicing, RNA nuclear export, protein translation, and membrane trafficking. Systems-wide studies would enhance our understanding of complex effects of SAHA on key cellular pathways and processes required for HIV reactivation.

RNA expression profiling by microarrays and RNA-Seq technology have been the foremost strategies for identifying genome-wide effects of a disease or a treatment. Studies using SAHA demonstrated downregulation of a subset of genes (Beliakova-Bethell et al., 2013; LaBonte et al., 2009; Wozniak et al., 2010), which is consistent with the existence of the secondary mechanisms of action and cannot be explained by chromatin decondensation. Transcriptomic methods are sensitive and capable of detecting the majority of the annotated genes; however, gene expression studies do not uncover the effects at the functional (protein) level. Liquid chromatography–mass spectrometry (LC–MS) based proteomics methods may be used to confirm functionality of transcripts. In addition, despite currently being less sensitive than

transcriptomics, LC–MS proteomics can identify the endophenotypic effects not otherwise reflected in the transcriptome including the occurrence of post-translationally modified proteins. We have therefore performed non-targeted quantitative iTRAQ proteomics experiments by ultra-high precision two-dimensional LC–MS using human primary CD4⁺ T cells treated with SAHA. By combining proteomic and transcriptomic datasets, we performed integrated data analysis for a more complete characterization of the secondary effects of SAHA. Based on protein function established in published literature, we propose that some of the observed effects of SAHA may have relevance to HIV reactivation, i.e., enhance or inhibit HIV transcription.

2. Materials and methods

2.1. CD4⁺ T cell isolation and SAHA treatment

Healthy donor volunteers provided written informed consent using a protocol approved by UCSD IRB. Primary CD4⁺ T cells were isolated and cultured as described previously (Beliakova-Bethell et al., 2013). All CD4⁺ T cell samples had >98% purity and <5% activation (HLA-DR⁺), as assessed by flow cytometry. Prior to treatment, cell concentration was adjusted to 2.5 million per ml with fresh medium. Cells were treated with 1 μ M SAHA or its solvent dimethyl sulfoxide (DMSO) and plated into 6-well tissue culture plates at 2 ml/well. Following 24 h of treatment, 10–15 million cells were collected after washing 4 times with 50 ml phosphate buffered saline to remove all traces of serum proteins. Cell pellets were frozen in dry ice/ethanol bath and stored at -80°C until protein isolation. A separate sample set was treated to validate gene expression by a method independent of high throughput profiling, droplet digital polymerase chain reaction (ddPCR) [(Beliakova-Bethell et al., 2014) and Supplementary Methods].

2.2. Proteomics and transcriptomics datasets

Protein was isolated and liquid chromatography–tandem mass spectrometry was performed as described previously (Al-Daghri et al., 2014; Manousopoulou et al., 2015; Papachristou et al., 2013). Briefly, 100 μ g of protein from each sample was extracted, reduced, alkylated, and proteolysed with trypsin. Peptides were labeled with iTRAQ 8-plex, pooled and subjected to two dimensions of liquid chromatography, and were characterized with nanocapillary ultra-performance liquid chromatography hyphenated with a nanospray ionization hybrid LTQ/FT-Orbitrap Elite ultra-high resolution mass spectrometry system. Unprocessed raw data files were searched by Proteome Discoverer for native, phosphorylated and acetylated peptides at a peptide false discovery rate of <1% against the human Uniprot proteome. For more details on protein preparation and proteomics, please refer to Supplementary Methods. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (Vizcaino et al., 2014) via the PRIDE partner repository (PXD002150). Transcriptomic data that assessed the effects of SAHA (1 μ M) in CD4⁺ T cells was obtained from our previously published SAHA dose responsive Illumina microarray dataset (Reardon et al., 2015) at the Gene Expression Omnibus (GSE66994).

2.3. Statistical analyses

To identify detected proteins, a statistical processing approach was used that accounts for key mass spectral features to reduce the effects of peptide co-isolation on the resulting iTRAQ reporter

ions and thus increase the accuracy of relative protein expression. Proteins were median-normalized and converted to $\log_2$ paired ratios (SAHA/DMSO). Protein expression values were obtained by averaging peptide intensity values and ratio-filtered. Filtering was not performed on acetylated or phosphorylated forms due to their intrinsic low abundance. Determination of differentially expressed proteins (DEPs), their phosphorylated (DPPs) and acetylated (DAPs) forms, and genes (DEGs) was done using *limma* (Smyth, 2004). Genes were further filtered on fold change ($|\log_2 \text{FC}| > 1$) for the protein interaction network (PIN). The PIN was constructed using Metacore™ from GeneGo, Inc. and visualized with Cytoscape (Shannon et al., 2003). Node color was subdivided into sections using the *MultiColoredNodes* package (Warsow et al., 2010). Gene ontology (GO) analysis was performed using Functional Analysis of Individual Microarray Expression (FAIME) (Yang et al., 2012). Gene membership for each GO term was determined with BioMart (Kasprzyk, 2011) using the Ensemble 78 Genes database and the GRCh38 Dataset (Flicek et al., 2014). GO term differential expression between the SAHA and DMSO control conditions was determined using a paired Student's *t*-test. In a discovery driven approach, proteins and protein GO terms with a nominal *p*-value (*p*) < 0.05 were considered significant. For genes and gene GO terms, a false discovery rate-corrected *p*-value (FDR) < 0.05 (Benjamini and Hochberg, 1995) was considered significant. Genes and proteins are referred to by official gene symbol except where noted. Please refer to the [Supplementary Methods](#) for details of data analysis procedures.

3. Results

3.1. Proteins and genes modulated by SAHA

The quantitative proteomics profiled 1547 proteins, identifying 185 DEPs, 18 DPPs and 4 DAPs ($p < 0.05$) between CD4+ T cells from 4 donors treated with SAHA or the DMSO control (Table S1). Identification of DPPs and DAPs was possible thanks to the in-depth and orthogonal two-dimensional liquid chromatographic separation of the tryptic peptides followed by their ultra-high resolution mass spectrometry. However, their non-targeted detection suggests that these *in vivo* modified proteins had higher abundance relative to other *in vivo* modified proteins not detected in this study that typically require prior enrichment for their analysis (Papachristou et al., 2013). To compare the effect of SAHA treatment between the proteome and transcriptome, microarray gene expression data were selected from our previous SAHA dose responsive study (Reardon et al., 2015). A paired analysis identified 2982 genes modulated by SAHA (FDR < 0.05) in CD4+ T cells from 6 donors (see Table S2 for the complete list of DEGs at the probe level). The modulation of a large number of these genes was confirmed at the protein level with 56 up- and 49 downregulated at both levels (Fig. 1). Even though an order of magnitude more DEGs were identified compared to DEPs, there was near complete agreement in the direction of modulation by SAHA when overlapped at the RNA and protein levels.

3.2. PINs for proteins and genes modulated by SAHA

It was hypothesized that the most important genes modulated by SAHA would be affected at several different levels (i.e., DEGs, DEPs, DPPs and DAPs). To integrate the 4 datasets, they were superimposed onto a PIN (Figs. 2 and S1). For visualization purposes, only genes and proteins with 5 or more connections are presented in Fig. 2, whereas the complete PIN is presented in Fig. S1. These PINs revealed that high mobility group (HMG) AT-hook 1 (*HMGAT1*) was upregulated at the RNA (DEG), protein (DEP) and

Fig. 1. Overlap between differentially expressed proteins (DEPs, $p < 0.05$) and genes (DEGs, FDR < 0.05). DEPs and DEGs were identified using linear modeling in R (package *limma*). The venn diagram was constructed using the *VennDiagram* package in R. Up- and downregulated genes and proteins are shown.

acetylated protein (DAP) levels. Heat shock protein 70 (HSP70) was represented in the PIN by 2 genes, *HSPA1A*, upregulated at the protein level, and *HSPA2*, upregulated at the RNA level. V-ets avian erythroblastosis virus E26 oncogene homolog 1 (*ETS1*) was downregulated by SAHA at the protein level, including total and phosphorylated (pS294) forms. A number of well-connected genes were modulated at the protein level only, e.g., lymphoid enhancer-binding factor 1 (*LEF1*), lysine (K)-specific demethylase 1A (*KDM1A*), and inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (*IKBKKB*). Another set of well-connected genes was regulated by SAHA only at the RNA level, e.g., v-MYC avian myelocytomatosis viral oncogene homolog (*MYC*), enhancer of zeste homolog 2 (*EZH2*), activator protein 1 (*AP-1*), and nuclear receptor coactivator 3 (*NCOA3*). While well-connected genes modulated at the protein level by SAHA may have regulatory roles for other genes, the role of genes modulated by SAHA at the RNA level would need further confirmation by more sensitive methods of protein detection.

3.3. Functional analysis of proteins and genes modulated by SAHA

To better understand the biological processes modulated by the well-connected proteins in the PIN, DEPs and DEGs were subjected to GO analysis using FAIME (Yang et al., 2012). An order of magnitude fewer proteins was detected by quantitative proteomics compared to genes detected by microarrays. Therefore, protein representation across the GO terms was assessed. A good correlation ($R^2 = 0.96$) was observed between the number of genes and proteins mapping to all the GO terms (Fig. S2). The exceptions were the GO terms *Plasma membrane proteins* and *Integral components of membrane*, which were under-represented for proteins, consistent with their hydrophobic properties and low abundance that result in poor extraction (Helbig et al., 2010). Overall, 1484 GO terms were upregulated and 935 downregulated by SAHA at the RNA level. At the protein level, 119 GO terms were upregulated and 146 downregulated. There was good overlap in GO terms ($N = 40$ up and $N = 20$ down) that were significantly modulated by SAHA at the RNA and protein levels (Fig. 3 and Table S3). Terms related to chromatin regulation, *Negative regulation of chromatin silencing* and *Nuclear euchromatin*, were upregulated by SAHA (Fig. 4). Terms related to histone acetylation and histone acetyltransferase complex were downregulated, as was observed previously with a lower

Fig. 4. GO terms significantly modulated by SAHA. GO terms modulated by SAHA were identified using FAIME. Terms related to known effects of SAHA and effects of SAHA relevant to HIV reactivation are shown. The heatmap represents values obtained by subtraction of a GO term average FAIME score for DMSO control from a GO term average FAIME score for SAHA (Δ FAIME Score). Red, the difference in FAIME score is greater than 0, and GO term is upregulated as the result of SAHA treatment. Blue, the difference in FAIME score is less than 0, and GO term is downregulated as the result of SAHA treatment. Count refers to the number of cells in the heatmap with the indicated difference in FAIME scores between SAHA and DMSO controls. P1 through P4 indicate samples used for protein analysis; G1 through G6 indicate samples used for gene expression analysis. The same genes and proteins were represented in the GO terms *Histone H4-K5 acetylation* and *Histone H4-K8 acetylation*, so these terms are depicted by a single row on the heatmap.

been detected in a transcriptomics approach, demonstrating the added value of a proteomics approach. Modulation of a protein may be a result of function of another protein whose transcript was upregulated. For example, upregulation of proteins required for translation (e.g., translation initiation factor *EIF5B* (Pestova et al., 2000)), may result in increase of translation from existing messenger RNAs (Schwanhauser et al., 2011). Protein expression may also be regulated post-translationally via activity of other proteins modulated by SAHA. For example, 3 proteins that regulate ubiquitination state were modulated by SAHA: E3 ubiquitin ligase *DTX3L*, E2 ubiquitin-conjugating enzyme *UBE2H*, and a deubiquitinase *USP13*. It is also possible that the changes in protein expression were the result of earlier transient changes in gene expression, which were not captured in the present study. In addition, even though enrichment for post-translationally modified peptides was not performed, changes in expression of 4 acetylated and 18 phosphorylated proteins after SAHA treatment were detected. Altogether, these data are consistent with the idea that SAHA may have much broader secondary effects beyond chromatin modification than previously recognized.

Among the detected 1547 proteins, 260 were differentially expressed only at the RNA, and not at the protein level, consistent with the idea that transcriptional effects of SAHA do not always translate into protein production (Mohammadi et al., 2014). However, this conclusion should be interpreted with caution due to the smaller sample size used in the proteomics part of the present study ($N = 4$ for the protein vs $N = 6$ for gene expression analyses). Since cells from different biological donors were used for proteomics and transcriptomics studies, it is also possible that some of the variation between identified DEPs and DEGs was the result of donor-to-donor differences in response to SAHA. However, donor-to-donor variation did not likely play a large role since whenever proteins and transcripts were both detected as differentially expressed, they were modulated in the same direction (Fig. 1), and expression of selected genes was confirmed by an independent method in an independent cohort (Fig. 5).

Fig. 5. Validation of gene expression by droplet digital PCR (ddPCR). Number of molecules of each target mRNA was normalized to the number of molecules of the normalizer mRNA (*RPL27*) in one nanogram of total RNA (expressed as copies per thousand *RPL27* molecules). Normality of the distribution and equality of variance in the DMSO and SAHA treated groups were assessed in the R computing environment, and either *t*-test (*HMGA1* and *ASF1A*) or Wilcoxon signed rank test (*AES*) were performed to assess the difference of expression induced by SAHA. The experiment was performed with cells from 6 independent donors. Error bars represent standard deviation. ** $p < 0.01$; * $0.01 < p < 0.05$.

4.2. Known effects of SAHA translate from the RNA to the protein level

Identification of GO terms related to previously recognized effects of SAHA at the RNA and protein levels gives confidence that the chosen proteomics methodology provides reliable data. For example, upregulation of genes encoding histones, but downregulation of genes encoding components of acetyltransferase complexes was observed previously by transcriptomics (Beliakova-Bethell et al., 2013). Downregulation of acetyltransferases suggests potential mechanisms by which cells attempt to regain control of acetylation following removal by SAHA of their ability to control acetylation through HDACs. Another process known to be downregulated by SAHA was T cell activation (Mohammadi et al., 2014; Reardon et al., 2015). Both *Positive regu-*

lation of T cell activation, and Positive regulation of T cell proliferation, were downregulated by SAHA at the RNA and protein levels (Fig. 4).

4.3. Effects of SAHA on RNA and proteins with a role in HIV reactivation

A number of HMG proteins (*HMGA1*, *HMG1*, *HMG20B*, *LEF1*) were modulated by SAHA at the protein and/or RNA levels. Like histones, HMG proteins regulate chromatin dynamics, dependent on post-translational modifications (Zhang and Wang, 2010). The most remarkable observation, made possible by using integrated proteomics and transcriptomics data, was the upregulation of *HMGA1* at the RNA and protein levels (Fig. 2, Tables S1 and S2), as well as a consistent upregulation of its acetylated form (Fig. S3). Two mechanisms by which *HMGA1* interferes with HIV transcription have been demonstrated. First, it competes with Tat for TAR binding and inhibits both basal and Tat-mediated HIV transcription (Eilebrecht et al., 2013). Second, *HMGA1* inhibits transcription of host genes, as well as HIV, by recruiting inactive p-TEFb to target promoters (Eilebrecht et al., 2014). Even though the observed increase of *HMGA1* protein was relatively small in the present study (1.15-fold), experimental overexpression (20% increase) (Eilebrecht et al., 2013) resulted in a measurable reduction of LTR activity proportionate to levels of *HMGA1* expression. Thus, upregulation of *HMGA1* by SAHA would appear to have an undesirable negative effect with respect to HIV reactivation. The *HMGA1* protein possesses 5 lysine residues that can be acetylated (Zhang et al., 2007). Of these, *ack64* and *ack70* have a known function in interferon-beta transcriptional switch in response to viral infection (Munshi et al., 2001). In the present study, the *ack14* form of *HMGA1* was upregulated by SAHA, for which no specific function has yet been demonstrated.

Identification of *HMGA1* (Fig. 2) prompted a more in-depth analysis of individual proteins that were modulated by SAHA. We performed a literature search on DEPs and “HIV” or “HIV latency” to determine whether any other proteins modulated by SAHA, besides *HMGA1*, have a role in activation or repression of HIV transcription (Table 1). Three of the proteins that were found in this search were modulated by SAHA at the RNA level as well (Table 1), and were confirmed by ddPCR (Fig. 5). More than half of the identified proteins were not modulated by SAHA at the RNA level. Change in RNA may be transient for some genes, as was noted by

Elliott and colleagues (Elliott et al., 2014). For example, *BRD2* was detected in their study at the RNA level 2 h post-treatment, while in the present study it was detected at the protein, but not the RNA level, 24 h post-treatment. Thus, a proteomics approach has added value to the transcriptomic approach by capturing some of the transient effects on genes at the protein level.

GO terms, which may be relevant to HIV reactivation and were modulated by SAHA at the RNA and protein levels, included *Regulation of I-kappaB kinase/NF-kappaB signaling*, *Protein binding involved in protein folding*, *Chaperone mediated protein folding requiring cofactor*, and *Autophagic vacuole* (Fig. 4 and Table S3). NFkB signaling is well recognized in HIV transcriptional activation (Nabel and Baltimore, 1987; Osborn et al., 1989). Interestingly, individual genes and proteins significantly upregulated by SAHA and mapping to *Regulation of I-kappaB kinase/NF-kappaB signaling* had opposite effects on NFkB activity. For example, *TNFA*, *F2RL1/ PAR2* (DEGs) and *HSPB1* (DEP) activate NFkB (Osborn et al., 1989; Parcellier et al., 2003; Sales et al., 2015) and thus promote HIV reactivation, while *ZFAND6* (DEG) represses NFkB (Chang et al., 2011). In addition, *IKBKB* (DEP) phosphorylates the inhibitor in the inhibitor/NFkB complex (Mercurio et al., 1997), causing dissociation of the inhibitor and activation of NFkB. Its downregulation by SAHA would thus have a negative effect with respect to HIV reactivation. Protein folding may have a role in HIV reactivation, because sequential actions of HSP70 and HSP90 are required for proper folding and stabilization of cyclin-dependent kinase 9 (Cdk9) and assembly of p-TEFb (O’Keeffe et al., 2000). Recently, the role of autophagy in HDACi-induced HIV reactivation and clearance of infected cells has become of interest. In monocyte-derived macrophages, intracellular HIV was shown to be degraded via canonical autophagy pathway upon reactivation with HDACis (Campbell et al., 2015). Lysosomal destabilization following HDACi treatment promoted death of HIV-infected cells, even with incomplete activation of HIV (Stankov et al., 2015). These results indicate the importance of autophagy when using SAHA, and other HDACis, for HIV reactivation.

4.4. Conclusions and implications

The present study is the first to our knowledge to identify proteins and their post-translationally modified forms modulated by SAHA in human primary CD4+ T cells. Combined with the analysis

Table 1

Proteins with a known role in HIV reactivation, up- or downregulated as the result of SAHA treatment. An implied effect of SAHA treatment on HIV transcription, based on the function of a given protein and the direction of its modulation by SAHA, is indicated in the rightmost column. *Plus sign*, possible positive effect on HIV transcription, e.g., resulting from upregulation of an activator or downregulation of a repressor. *Minus sign*, possible negative effect on HIV transcription, e.g., resulting from downregulation of an activator or upregulation of a repressor. Asterisk (*) indicates that for the heat shock protein 70, one gene (*HSPA1A*) was modulated by SAHA at the protein level only, while another gene (*HSPA2*) was modulated only at the transcript level.

Description	Protein (gene symbol)	Gene name	Reference(s)	Transcript modulated?	Effect on HIV transcription
<i>Proteins that act to activate HIV transcription</i>					
Upregulated by SAHA	<i>HSPA1A</i>	Heat shock 70 kDa protein 1A	O’Keeffe et al. (2000)	No/yes*	+
	<i>KDM1A</i>	Lysine (K)-specific demethylase 1A	Sakane et al. (2011)	No	+
Downregulated by SAHA	<i>ETS1</i>	v-ets avian erythroblastosis virus E26 oncogene homolog 1	Bassuk et al. (1997); Posada et al. (2000); Sieweke et al. (1998); Yang et al. (2009)	No	–
	<i>LEF1</i>	Lymphoid enhancer-binding factor 1	Sheridan et al. (1995)	No	–
	<i>IKBKB</i>	Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta	Mercurio et al. (1997); Nabel and Baltimore (1987)	No	–
<i>Proteins that act to inhibit HIV transcription</i>					
Upregulated by SAHA	<i>HMGA1</i>	High mobility group AT-hook 1	Eilebrecht et al. (2014,2013)	Yes	–
	<i>ASF1A</i>	Anti-silencing function 1A histone chaperone	Gallastegui et al. (2011)	Yes	–
	<i>BRD2</i>	Bromodomain containing 2	Boehm et al. (2013)	No	–
	<i>BRDT</i>	Bromodomain, testis-specific	Biggrove et al. (2007)	No	–
Downregulated by SAHA	<i>AES</i>	Amino-terminal enhancer of split	Tetsuka et al. (2000)	Yes	+
	<i>ARID1B</i> (BAF250)	AT rich interactive domain 1B (SWI1-like)	Mahmoudi (2012); Rafati et al. (2011)	No	+

of induced transcriptomic changes, this study demonstrates global regulatory networks affected by SAHA treatment and enhances our understanding of the secondary mechanisms of SAHA action. Expression of a number of genes and proteins with previously reported roles in HIV transcriptional control was modulated by SAHA; some of these effects would appear to be inhibitory for HIV reactivation. Identification of these counter-regulatory effects of SAHA on HIV induction have the potential to strongly impact selection and modification of HDACis and prioritization of other LRAs for future evaluations and advancement to clinical trials. Better potencies for HIV reactivation of the HDACis Romidepsin (Wei et al., 2014) and Panobinostat (Rasmussen et al., 2013) may be due to the lower impact of secondary negative effects possessed by SAHA, which warrants further investigation. Synergistic HIV reactivation when using SAHA with Protein Kinase C (PKC) agonists, such as prostratin and bryostatin (Laird et al., 2015; Williams et al., 2004), may be due to negating adverse effects of SAHA on NF κ B signaling pathway by these LRAs. Prostratin and bryostatin are not suitable for use *in vivo* due to side effects or limited availability; however, other PKCs, such as Ingenol derivatives (Jiang et al., 2014; José et al., 2014), warrant further testing in combination with SAHA using cells from HIV-infected patients *ex vivo*. Proteome profiling performed in this study revealed a number of potential counter-regulatory effects of SAHA not present at the transcript level. We would therefore recommend using transcriptomic and proteomic profiling as two complementary techniques, transcript profiling being a more sensitive method, and protein profiling for confirmation of transcripts and detection of protein-specific effects.

Acknowledgements

We gratefully acknowledge all volunteers at UCSD, who contributed blood, and Merck and Co., Inc., who graciously provided SAHA used in this study. We are indebted to Mr. Roger Allsopp and Mr. Derek Coates for their enthusiasm, fund raising and vision in promoting the FT-MS proteomics platform at the University of Southampton. Thanks to Dr. Xunli Zhang for the kind use of the high-performance liquid chromatography system. We acknowledge the use of the IRIDIS High Performance Computing Facility, and associated support services, such as the Bioinformatics Core, at the University of Southampton, in the completion of this work. We thank the PRIDE team for the proteomics data processing and repository assistance. This research was supported by the Grants from the National Institute of Health, Martin Delaney Collaboratory of AIDS Researchers for Eradication (CARE, U19 AI 096113), through the research infrastructure provided by the UCSD Center for AIDS Research (CFAR, AI 36214) and the James B. Pendleton Charitable Trust. The Wessex Cancer Trust and Medical Research, UK, Hope for Guernsey and the University of Southampton 'Annual Adventures in Research' Grant, made it possible to establish the proteomics infrastructure and its use for this study. This material is based upon work supported in part by the Department of Veterans Affairs (VA), Veterans Health Administration, Office of Research and Development. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. The sponsors of this research were not involved in the study design, collection or interpretation of the data, manuscript preparation, or the decision to submit the article for publication.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.antiviral.2015.09.002>.

References

- Al-Daghri, N.M., Al-Attas, O.S., Johnston, H.E., Singhanian, A., Alokail, M.S., Alkharfy, K. M., Abd-Alrahman, S.H., Sabico, S.L., Roumeliotis, T.I., Manousopoulou-Garbis, A., Townsend, P.A., Woelk, C.H., Chrousos, G.P., Garbis, S.D., 2014. Whole serum 3D LC-nESI-FTMS quantitative proteomics reveals sexual dimorphism in the milieu intérieur of overweight and obese adults. *J. Proteome Res.* 13, 5094–5105.
- Archin, N.M., Bateson, R., Tripathy, M.K., Crooks, A.M., Yang, K.-H., Dahl, N.P., Kearney, M.F., Anderson, E.M., Coffin, J.M., Strain, M.C., Richman, D.D., Robertson, K.R., Kashuba, A.D., Bosch, R.J., Hazuda, D.J., Kuruc, J.D., Eron, J.J., Margolis, D.M., 2014. HIV-1 expression within resting CD4⁺ T cells after multiple doses of vorinostat. *J. Infect. Dis.* 210, 728–735.
- Archin, N.M., Liberty, A.L., Kashuba, A.D., Choudhary, S.K., Kuruc, J.D., Crooks, A.M., Parker, D.C., Anderson, E.M., Kearney, M.F., Strain, M.C., Richman, D.D., Hudgens, M.G., Bosch, R.J., Coffin, J.M., Eron, J.J., Hazuda, D.J., Margolis, D.M., 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. *Nature* 487, 482–485.
- Bantscheff, M., Hopf, C., Savitski, M.M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., Boesche, M., Dellling, M., Dimpelfeld, B., Eberhard, D., Huthmacher, C., Mathieson, T., Poekel, D., Reader, V., Strunk, K., Sweetman, G., Kruse, U., Neubauer, G., Ramsden, N.G., Drewes, G., 2011. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. *Nat. Biotech.* 29, 255–265.
- Bassuk, A.G., Anandappa, R.T., Leiden, J.M., 1997. Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells. *J. Virol.* 71, 3563–3573.
- Beliakova-Bethell, N., Massanella, M., White, C., Lada, S.M., Du, P., Vaida, F., Blanco, J., Spina, C.A., Woelk, C.H., 2014. The effect of cell subset isolation method on gene expression in leukocytes. *Cytometry A* 85A, 94–104.
- Beliakova-Bethell, N., Zhang, J., Singhanian, A., Lee, V., Terry, V., Richman, D.D., Spina, C.A., Woelk, C.H., 2013. Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4⁺ T cells. *AIDS* 27, 29–37.
- Benjamini, Y., Hochberg, Y., 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc., B Meth.* 57, 289–300.
- Bisgrove, D.A., Mahmoudi, T., Henklein, P., Verdin, E., 2007. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. *Proc. Natl. Acad. Sci. U S A* 104, 13690–13695.
- Boehm, D., Calvanese, V., Dar, R.D., Xing, S., Schroeder, S., Martins, L., Aull, K., Li, P.-C., Planellas, V., Bradner, J.E., Zhou, M.-M., Siliciano, R.F., Weinberger, L., Verdin, E., Ott, M., 2013. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. *Cell Cycle* 12, 452–462.
- Campbell, G.R., Bruckman, R.S., Chu, Y.-L., Spector, S.A., 2015. Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. *J. Biol. Chem.* 290, 5028–5040.
- Chang, E.-J., Ha, J., Kang, S.-S., Lee, Z.H., Kim, H.-H., 2011. AWP1 binds to tumor necrosis factor receptor-associated factor 2 (TRAF2) and is involved in TRAF2-mediated nuclear factor-kappaB signaling. *Int. J. Biochem. Cell Biol.* 43, 1612–1620.
- Choudhary, C., Kumar, C., Gnäd, F., Nielsen, M.L., Rehman, M., Walther, T.C., Olsen, J., Mann, M., 2009. Lysine acetylation targets protein complexes and co-regulates major cellular functions. *Science* 325, 834–840.
- Contreras, X., Schwenker, M., Chen, C.-S., McCune, J.M., Deeks, S.G., Martin, J., Peterlin, B.M., 2009. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. *J. Biol. Chem.* 284, 6782–6789.
- Eilebrecht, S., Le Douce, V., Riclet, R., Targat, B., Hallay, H., Van Driessche, B., Schwartz, C., Robette, G., Van Lint, C., Rohr, O., Benecke, A.G., 2014. HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters. *Nucleic Acids Res.* 42, 4962–4971.
- Eilebrecht, S., Wilhelm, E., Benecke, B.-J., Bell, B., Benecke, A.G., 2013. HMGA1 directly interacts with TAR to modulate basal and Tat-dependent HIV transcription. *RNA Biol.* 10, 436–444.
- Elliott, J.H., Wightman, F., Solomon, A., Ghneim, K., Ahlers, J., Cameron, M.J., Smith, M.Z., Spelman, T., McMahon, J., Velayudham, P., Brown, G., Roney, J., Watson, J., Prince, M.H., Hoy, J.F., Chomont, N., Fromentin, R., Procopio, F.A., Zeidan, J., Palmer, S., Odeval, L., Johnstone, R.W., Martin, B.P., Sinclair, E., Deeks, S.G., Hazuda, D.J., Cameron, P.U., Sékaly, R.-P., Lewin, S.R., 2014. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. *PLoS Pathog.* 10, e1004473.
- Flieck, P., Amode, M.R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., Gil, L., Girón, C.G., Gordon, L., Hourlier, T., Hunt, S., Johnson, N., Juettemann, T., Kähäri, A.K., Keenan, S., Kulesha, E., Martin, F.J., Maurel, T., McLaren, W.M., Murphy, D.N., Nag, R., Overduin, B., Pignatelli, M., Pritchard, B., Pritchard, E., Riat, H.S., Ruffier, M., Sheppard, D., Taylor, K., Thormann, A., Trevanion, S.J., Vullo, A., Wilder, S.P., Wilson, M., Zadiissa, A., Aken, B.L., Birney, E., Cunningham, F., Harrow, J., Herrero, J., Hubbard, T.J.P., Kinsella, R., Muffato, M., Parker, A., Spudich, G., Yates, A., Zerbino, D.R., Searle, S.M.J., 2014. Ensembl 2014. *Nucleic Acids Res.* 42, D749–D755.
- Gallastegui, E., Millán-Zambrano, G., Terme, J.-M., Chávez, S., Jordan, A., 2011. Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. *J. Virol.* 85, 3187–3202.
- Helbig, A.O., Heck, A.J.R., Slijper, M., 2010. Exploring the membrane proteome—Challenges and analytical strategies. *J. Proteomics* 73, 868–878.

- Jiang, G., Mendes, E.A., Kaiser, P., Sankaran-Walters, S., Tang, Y., Weber, M.G., Melcher, G.P., Thompson, G.R., Tanuri, A., Pianowski, L.F., Wong, J.K., Dandekar, S., 2014. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cd-NF- κ B signaling. *AIDS* 28, 1555–1566.
- José, D.P., Bartholomeeusen, K., da Cunha, R.D., Abreu, C.M., Glinski, J., da Costa, T.B.F., Rabay, A.F.M.B., Filho, L.F.P., Dudycz, L.W., Ranga, U., Peterlin, B.M., Pianowski, L.F., Tanuri, A., Aguiar, R.S., 2014. Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. *Virology* 462–463, 328–339.
- Kasprzyk, A., 2011. BioMart: driving a paradigm change in biological data management. Database (Oxford) 2011, bar049.
- LaBonte, M., Wilson, P., Fazzone, W., Groshen, S., Lenz, H.-J., Ladner, R., 2009. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. *BMC Med. Genomics* 2, 67.
- Laird, G.M., Bullen, C.K., Rosenbloom, D.I.S., Martin, A.R., Hill, A.L., Durand, C.M., Siliciano, J.D., Siliciano, R.F., 2015. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. *J. Clin. Invest.* 125, 1901–1912.
- Mahmoudi, T., 2012. The BAF complex and HIV latency. *Transcription* 3, 171–176.
- Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R., Pazdur, R., 2007. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-Cell lymphoma. *Oncologist* 12, 1247–1252.
- Manousopoulou, A., Woo, J., Woelk, C.H., Johnston, H.E., Singhania, A., Hawkes, C., Garbis, S.D., Carare, R.O., 2015. Are you also what your mother eats? Distinct proteomic portrait as a result of maternal high-fat diet in the cerebral cortex of the adult mouse. *Int. J. Obes.* 39, 1325–1328.
- Matalon, S., Rasmussen, T.A., Dinarello, C.A., 2011. Histone deacetylase inhibitors for purging HIV-1 from latent reservoir. *Mol. Med.* 17, 466–472.
- Mercurio, F., Zhu, H., Murray, B.W., Shevchenko, A., Bennett, B.L., Li, J.W., Young, D. B., Barbosa, M., Mann, M., Manning, A., Rao, A., 1997. IKK-1 and IKK-2: cytokine-activated I κ B kinases essential for NF- κ B activation. *Science* 278, 860–866.
- Mohammadi, P., di Iulio, J., Muñoz, M., Martinez, R., Bartha, I., Cavassini, M., Thorball, C., Fellay, J., Beerenwinkel, N., Ciuffi, A., Telenti, A., 2014. Dynamics of HIV latency and reactivation in a primary CD4+ T cell model. *PLoS Pathog.* 10, e1004156.
- Munshi, N., Agaloti, T., Lomardas, S., Merika, M., Chen, G., Thanos, D., 2001. Coordination of a transcriptional switch by HMG(Y) acetylation. *Science* 293, 1133–1136.
- Nabel, G., Baltimore, D., 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. *Nature* 326, 711–713.
- O’Keeffe, B., Fong, Y., Chen, D., Zhou, S., Zhou, Q., 2000. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/Cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. *J. Biol. Chem.* 275, 279–287.
- Osborn, L., Kunkel, S., Nabel, G.J., 1989. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. *Proc. Natl. Acad. Sci. USA* 86, 2336–2340.
- Papachristou, E.K., Roumeliotis, T.I., Chrysagi, A., Trigoni, C., Charvalos, E., Townsend, P.A., Pavlakis, K., Garbis, S.D., 2013. The shotgun proteomic study of the human ThinPrep cervical smear using iTRAQ mass-tagging and 2D LC-FT-Orbitrap-MS: the detection of the human papillomavirus at the protein level. *J. Proteome Res.* 12, 2078–2089.
- Parcellier, A., Schmitt, E., Gurbuxani, S., Seigneurin-Berny, D., Pance, A., Chantôme, A., Plenchette, S., Khochbin, S., Solary, E., Garrido, C., 2003. HSP27 is a ubiquitin-binding protein involved in I- κ B α proteasomal degradation. *Mol. Cell. Biol.* 23, 5790–5802.
- Pestova, T.V., Lomakin, I.B., Lee, J.H., Choi, S.K., Dever, T.E., Hellen, C.U.T., 2000. The joining of ribosomal subunits in eukaryotes requires eIF5B. *Nature* 403, 332–335.
- Posada, R., Pettoello-Mantovani, M., Sieweke, M., Graf, T., Goldstein, H., 2000. Suppression of HIV type 1 replication by a dominant-negative Ets-1 mutant. *AIDS Res. Hum. Retroviruses* 16, 1981–1989.
- Rafati, H., Parra, M., Hakre, S., Moshkin, Y., Verdin, E., Mahmoudi, T., 2011. Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. *PLoS Biol.* 9, e1001206.
- Rasmussen, T.A., Søgaard, O.S., Brinkmann, C., Wightman, F., Lewin, S.R., Melchjorsen, J., Dinarello, C., Østergaard, L., Tolstrup, M., 2013. Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation. *Hum. Vaccine Immunother.* 9, 993–1001.
- Reardon, B., Beliakov-Bethell, N., Spina, C.A., Zhang, J.X., Singhania, A., Richman, D. D., Woelk, C.H., 2015. Dose-responsive gene expression changes in suberoylanilide hydroxamic acid-treated resting CD4+ T cells. *AIDS*. In press.
- Richman, D.D., Margolis, D.M., Delaney, M., Greene, W.C., Hazuda, D., Pomerantz, R. J., 2009. The challenge of finding a cure for HIV infection. *Science* 323, 1304–1307.
- Sakane, N., Kwon, H.-S., Pagans, S., Kaehle, K., Mizusawa, Y., Kamada, M., Lassen, K. G., Chan, J., Greene, W.C., Schnoelzer, M., Ott, M., 2011. Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). *PLoS Pathog.* 7, e1002184.
- Sales, K.U., Friis, S., Konkel, J.E., Godiksen, S., Hatakeyama, M., Hansen, K.K., Rogatto, S.R., Szabo, R., Vogel, L.K., Chen, W., Gutkind, J.S., Bugge, T.H., 2015. Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis. *Oncogene* 34, 346–356.
- Schwanhauss, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., Selbach, M., 2011. Global quantification of mammalian gene expression control. *Nature* 473, 337–342.
- Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B., Ideker, T., 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* 13, 2498–2504.
- Sheridan, P.L., Sheline, C.T., Cannon, K., Voz, M.L., Pazin, M.J., Kadonaga, J.T., Jones, K. A., 1995. Activation of the HIV-1 enhancer by the LEF-1 HMG protein on nucleosome-assembled DNA *in vitro*. *Genes Dev.* 9, 2090–2104.
- Shirakawa, K., Chavez, L., Hakre, S., Calvanese, V., Verdin, E., 2013. Reactivation of latent HIV by histone deacetylase inhibitors. *Trends Microbiol.* 21, 277–285.
- Sieweke, M.H., Tekotte, H., Jarosch, U., Graf, T., 1998. Cooperative interaction of ets-1 with USF-1 required for HIV-1 enhancer activity in T cells. *EMBO J.* 17, 1728–1739.
- Smyth, K., 2004. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. *Stat. Appl. Genet. Mol. Biol.* 3, 1–25.
- Stankov, M., Suhr, C., Lin, H., Panayotova-Dimitrova, D., Goffinet, C., Behrens, G., 2015. Latent HIV-1 reactivation and lysosomal destabilization synergize to host cell death. Program and abstracts of the 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
- Tetsuka, T., Uranishi, H., Imai, H., Ono, T., Sonta, S.-i., Takahashi, N., Asamitsu, K., Okamoto, T., 2000. Inhibition of nuclear factor- κ B-mediated transcription by association with the amino-terminal enhancer of split, a Groucho-related protein lacking WD40 repeats. *J. Biol. Chem.* 275, 4383–4390.
- Vizcaíno, J.A., Deutsch, E.W., Wang, R., Csordas, A., Reisinger, F., Ríos, D., Dienes, J.A., Sun, Z., Farrah, T., Bandeira, N., Binz, P.-A., Xenarios, I., Eisenacher, M., Mayer, G., Gatto, L., Campos, A., Chalkley, R.J., Kraus, H.-J., Albar, J.P., Martinez-Bartolomé, S., Apweiler, R., Omenn, G.S., Martens, L., Jones, A.R., Hermjakob, H., 2014. ProteomeXchange provides globally co-ordinated proteomics data submission and dissemination. *Nat. Biotechnol.* 32, 223–226.
- Warsow, G., Greber, B., Falk, S.S.I., Harder, C., Siatkowski, M., Schordan, S., Som, A., Endlich, N., Schöler, H., Repsilber, D., Endlich, K., Fuellen, G., 2010. ExprEssence – revealing the essence of differential experimental data in the context of an interaction/regulation network. *BMC Syst. Biol.* 4, 164.
- Wei, D.G., Chiang, V., Fyne, E., Balakrishnan, M., Barnes, T., Graupe, M., Hesselgesser, J., Irrinki, A., Murry, J.P., Stepan, G., Stray, K.M., Tsai, A., Yu, H., Spindler, J., Kearney, M., Spina, C.A., McMahon, D., Lalezari, J., Sloan, D., Mellors, J., Geleziunas, R., Cihlar, T., 2014. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. *PLoS Pathog.* 10, e1004071.
- Williams, S., Samuel, A., Chen, L.-F., Kwon, H., Fenard, D., Bisgrove, D., Verdin, E., Greene, W.C., 2004. Prostratin antagonizes HIV latency by activating NF- κ B. *J. Biol. Chem.* 279, 42008–42017.
- Wozniak, M.B., Villuendas, R., Bischoff, J.R., Aparicio, C.B., Martínez Leal, J.F., de La Cueva, P., Rodríguez, M.E., Herreros, B., Martín-Pérez, D., Longo, M.I., Herrera, M., Piris, M.A., Ortiz-Romero, P.L., 2010. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. *Haematologica* 95, 613–621.
- Yang, H.-C., Shen, L., Siliciano, R.F., Pomerantz, J.L., 2009. Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. *Proc. Natl. Acad. Sci. U S A* 106, 6321–6326.
- Yang, X., Regan, K., Huang, Y., Zhang, Q., Li, J., Seiwert, T.Y., Cohen, E.E.W., Xing, H.R., Lussier, Y.A., 2012. Single sample expression-anchored mechanisms predict survival in head and neck cancer. *PLoS Comput. Biol.* 8, e1002350.
- Ylisastigui, L., Archin, N.M., Lehrman, G., Bosch, R.J., Margolis, D.M., 2004. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. *AIDS* 18, 1101–1108.
- Zhang, Q., Wang, Y., 2010. HMG modifications and nuclear function. *Biochim. Biophys. Acta* 1799, 28.
- Zhang, Q., Zhang, K., Zou, Y., Perna, A., Wang, Y., 2007. A quantitative study on the in-vitro and in-vivo acetylation of high mobility group A1 proteins. *J. Am. Soc. Mass Spectrom.* 18, 1569–1578.

Glossary

- cART: combination antiretroviral therapy
DMSO: dimethyl sulfoxide
FAIME: Functional Analysis of Individual Microarray Expression
FDA: Food and Drug Administration
FDR: false discovery rate-adjusted *p*-value
GO: gene ontology
HDAC: histone deacetylase
HDACi: histone deacetylase inhibitor
HIV: human immunodeficiency virus
HMG: high mobility group
IRB: Institutional Review Board
iTRAQ: isobaric tags for relative and absolute quantitation
LTR: long terminal repeat
PIN: protein interaction network
PKC: protein kinase C
p-TEFb: positive transcription elongation factor
SAHA: suberoylanilide hydroxamic acid